)
)
SCYNEXIS Investor Relations Material
Latest events
Q4 2022 & Business Update
SCYNEXIS
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from SCYNEXIS Inc
Access all reports
SCYNEXIS Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapies for fungal infections. The company's lead product, based on a novel antifungal platform, is designed to address severe and drug-resistant fungal infections in both hospital and outpatient settings. SCYNEXIS develops treatments for conditions with significant unmet medical needs, with a particular emphasis on antifungal agents targeting life-threatening infections. The company is headquartered in Jersey City, USA, and its shares are listed on the NASDAQ.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
SCYX
Country
🇺🇸 United States